Venafro, Italy

Elisa Perissutti

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 10.3

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Elisa Perissutti: Innovator in Pharmaceutical Compositions

Introduction

Elisa Perissutti is a notable inventor based in Venafro, Italy. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions for respiratory treatments. With a total of 3 patents, her work has the potential to impact the lives of many suffering from respiratory conditions.

Latest Patents

One of her latest patents is titled "Budesonide 21-phosphate salts and pharmaceutical compositions containing the same." This invention relates to salts of budesonide 21-phosphate combined with β2 adrenergic agonists, such as formoterol. The pharmaceutical compositions developed from this invention are aimed at treating respiratory inflammatory pathologies, obstructive pathologies, and allergen-induced airway dysfunctions. Additionally, she has patented "Montelukast salts and pharmaceutical compositions containing the same." This invention also focuses on salts of Montelukast with β2 adrenergic agonists, providing similar therapeutic benefits for respiratory conditions.

Career Highlights

Elisa Perissutti is currently associated with Genetic S.p.a., where she continues to innovate in the pharmaceutical sector. Her work is characterized by a commitment to improving treatment options for patients with respiratory issues.

Collaborations

Throughout her career, she has collaborated with notable colleagues, including Giuseppe Caliendo and Giuseppe Cirino. These partnerships have contributed to her success and the advancement of her inventions.

Conclusion

Elisa Perissutti stands out as a dedicated inventor in the pharmaceutical industry, with her patents reflecting a strong focus on improving respiratory health. Her contributions are poised to make a significant difference in the treatment of respiratory conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…